Legal Library: Search

A Florida-based company that has promoted its Isoprex supplement to older adults as a miracle cure for pain and joint inflammation has agreed to a settlement with the FTC that bars the company from continuing to make its unproven claims. In September 2020, the FTC announced it was sending refunds totaling more than $76,000 to consumers who bought the deceptively marketed product.

In April 2019, the FTC announced that a federal district court judge ordered Srinubabu Gedela and his companies to pay more than $50.1 million to resolve FTC charges that they made deceptive claims about the nature of their conferences and publications, and hid steep publication fees. The court ruling resolved a 2016 Commission complaint alleging that Gedela and the companies falsely advertised online scientific and medical academic journals and international conferences, and deceptively claimed the journals provided authors with rigorous peer review and editorial boards comprised of prominent academics.

Under a settlement with the Federal Trade Commission announced in March 2020, the marketers of an electrical nerve stimulation device called Quell have agreed to pay $4 million and stop making deceptive claims that the device treats pain throughout the body when placed below the knee. They also will stop claiming the device’s efficacy is clinically proven and that it has been cleared by the FDA to treat pain throughout the body. In early September 2020, the FTC announced it was returning almost $3.9 million to defrauded consumers.

Reckitt Benckiser Group plc has agreed to pay $50 million to settle Federal Trade Commission charges that it violated the antitrust laws through a deceptive scheme to thwart lower-priced generic competition to its branded drug Suboxone. According to the complaint, before the generic versions of Suboxone tablets became available, Reckitt and its former subsidiary Reckitt Benckiser Pharmaceuticals, now known as Indivior, Inc., developed a dissolvable oral film version of Suboxone and worked to shift prescriptions to this patent-protected film. Worried that doctors and patients would not want to switch to Suboxone Film, Reckitt allegedly employed a “product hopping” scheme where the company misrepresented that the film version of Suboxone was safer than Suboxone tablets because children are less likely to be accidentally exposed to the film product. Invidior has agreed to pay an additional $10 million to settle FTC charges.

In their complaint against Madera Merchant Services and B&P Enterprises, the Federal Trade Commission and the Ohio Attorney General allege that the companies generated and processed remotely created payment orders (RCPOs) or checks that allowed many unscrupulous merchants, including deceptive telemarketing schemes, to withdraw money from their victims’ bank accounts. The FTC’s Telemarketing Sales Rules (TSR) specifically prohibits the use of RCPOs in connection with telemarketing sales. The court issued temporary restraining orders against Madera Merchant Services and B&P Enterprises, halting their operations and freezing their assets. The defendants and the FTC have agreed to a stipulated Preliminary Injunction in this matter. The defendants agreed to a settlement with the FTC in 2020 that permanently banned them from payment processing.

In January 2020, the sellers of a pill called ReJuvenation settled FTC charges that they deceptively claimed that their product is a virtual cure-all for age-related ailments—including cell damage, heart attack damage, brain damage, blindness, and deafness. The orders settling the FTC’s complaint prohibit the defendants from making such claims unless they are true and supported by scientific evidence. The orders also require payment of $660,000, which the Commission may use to provide refunds to defrauded consumers. In June 2020, the FTC announced it was sending checks totaling more than $149,000 to consumers who bought the product.

The Federal Trade Commission is sending refunds to individuals who lost money to a company called I Works, which operated deceptive "trial" memberships and bogus government-grant and money-making schemes in 2010. 

In March 2020, Nevada-based Health Center, Inc. (HCI) and its owner Peggy Pearce agreed to halt their allegedly deceptive advertising claims about three “cure-all” health and wellness products that targeted older consumers nationwide, in a settlement with the Federal Trade Commission. The order settling the FTC’s complaint prohibits HCI and Pearce from such deceptive conduct and imposes a partially suspended monetary judgment.

In April 2019, the FTC announced that 16 defendants settled charges that they deceptively marketed “cognitive improvement” supplements using sham news websites containing false and unsubstantiated efficacy claims, references to non-existent clinical studies, and fraudulent consumer and celebrity endorsements. The FTC also alleged the defendants used affiliate marketers to make deceptive claims for products including Geniux, Xcel, EVO, and Ion-Z. The settlements ban the defendants from engaging in similar conduct in the future. In February 2020, the Commission announced it was sending refund checks totaling over $551,000 to defrauded consumers.

Office Depot, Inc. and its tech support software provider Support.com, Inc., settled Federal Trade Commission allegations that the two companies tricked customers into buying millions of dollars' worth of computer repair and technical services by deceptively claiming their software had found malware on the customers' computers. 

In February 2020, two Oregon-based media production companies and their owner agreed to settle FTC charges that they deceptively pitched “exclusive” advertising placements to small businesses and misled them about when the ads would be printed and distributed. The order settling the FTC’s complaint bans the defendants from such deceptive conduct and requires them to pay $100,000.

The Federal Trade Commission filed an administrative complaint against data analytics company Cambridge Analytica, and filed settlements for public comment with Cambridge Analytica’s former chief executive and an app developer who worked with the company, alleging they employed deceptive tactics to harvest personal information from tens of millions of Facebook users for voter profiling and targeting.

Former Cambridge Analytica, LLC CEO Alexander Nix and Aleksandr Kogan, an app developer who worked with the company, settled Federal Trade Commission allegations that they used deceptive tactics to collect personal information from tens of millions of Facebook users for voter profiling and targeting. 

In June 2018, the final two defendants among a group of California-based marketers were permanently barred from the deceptive marketing and billing tactics used in connection with selling skincare products offered to consumers with supposedly “risk-free” trials. The court order settled the charges against them, which the FTC announced in mid-2015. In all, 32 defendants who sold AuraVie, Dellure, LéOR Skincare, and Miracle Face Kit branded skincare products agreed to court orders with the FTC or had default orders entered against them. In November 2019, the FTC announced it was returning over $1.8 million to consumers who bought the deceptively marketed products.

LifeLock paid $100 million to settle Federal Trade Commission contempt charges that it violated the terms of a 2010 federal court order that requires the company to secure consumers' personal information and prohibits the company from deceptive advertising. 

In February 2017, the FTC and the Maine AG’s office announced a complaint and three settlements with dietary supplement marketers who allegedly used radio infomercials deceptively formatted as talk shows and print ads featuring fictitious endorsers to advertise supplements purporting to improve memory and to reduce back and joint pain. The settlement orders resolving charges against the named in the complaint bar them from making similar deceptive claims, and prohibit them from engaging in a wide range of marketing practices that have caused serious financial injury to consumers. In April 2015, the FTC sent refunds to consumers who bought one of the company deceptively marketed supplements, CogniPrin. In August 2019, the FTC send refunds to consumers who bought FlexiPrin, another supplement the company sold.

In December 2018, officers of a company that marketed and sold Nobetes, a pill they claimed treats diabetes, settled an FTC complaint alleging that the advertising claims for the product are false or unsubstantiated. The order settling the FTC’s complaint prohibits the company and its officers from undertaking future deceptive practices, including making unsubstantiated health claims, misleading consumers about the terms of “free trial” offers, billing consumers without their consent, and other practices related to the use of “expert” endorsements and consumer testimonials. In addition, it requires them to pay money to provide refunds to consumers who bought the product. In August 2019, the FTC returned $60,791 to these consumers.